Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer.

Abstract:

BACKGROUND:The estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) statuses are frequently discordant between the primary tumor and metastatic lesions in metastatic breast cancer. This can have important therapeutic implications. PATIENTS AND METHODS:In all, 541 patients with available receptor statuses from both primary tumor and metastatic lesion treated at Heidelberg and Tuebingen University Hospitals between 1982 and 2018 were included. RESULTS:Statistically significant discordance rates of 14% and 32% were found for ER and PR. HER2 status was statistically insignificantly discordant in 15% of patients. Gain in HER2 positivity was associated with an improved overall survival, whereas loss of HR positivity was associated with worse overall survival. Antiendocrine treatment differed in 20% of cases before and after biopsy and HER2-directed treatment in 14% of cases. CONCLUSIONS:Receptor statuses are discordant between primary tumor and metastasis in a considerable fraction of patients with metastatic breast cancer. Next to a highly presumed predictive value with respect to efficacy of endocrine and HER2-targeted therapy, discordance seems to provide prognostically relevant information. Where feasible, metastatic lesions should be biopsied in accordance with current guidelines.

authors

Walter V,Fischer C,Deutsch TM,Ersing C,Nees J,Schütz F,Fremd C,Grischke EM,Sinn P,Brucker SY,Schneeweiss A,Hartkopf AD,Wallwiener M

doi

10.1007/s10549-020-05746-8

subject

Has Abstract

pub_date

2020-08-01 00:00:00

pages

137-144

issue

1

eissn

0167-6806

issn

1573-7217

pii

10.1007/s10549-020-05746-8

journal_volume

183

pub_type

杂志文章
  • The 17q23 amplicon and breast cancer.

    abstract::A novel region of amplification in breast tumors was recently identified on chromosome 17q23. Extensive mapping of the amplicon by Southern blotting and fluorescence in situ hybridization (FISH) in breast cancer cell lines determined that the amplicon can be up to 4 Mbp in size and may contain 50 genes. Copy number an...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1023/a:1023081624133

    authors: Sinclair CS,Rowley M,Naderi A,Couch FJ

    更新日期:2003-04-01 00:00:00

  • Adjuvant systemic therapy: state of the art, 1989.

    abstract::After more than 100 reported randomized trials of systemic adjuvant therapy in breast cancer, it is clear that this therapy will prolong the time to recurrence and the survival time significantly, at least in some patient subsets. But there is less than complete agreement as to which subsets, which therapies, how much...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验,评审

    doi:10.1007/BF01805971

    authors: Henderson IC

    更新日期:1989-10-01 00:00:00

  • Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer.

    abstract::The aim of this study is to identify and validate copy number aberrations in early-stage primary breast tumors associated with bone or non-bone metastasis. Whole-genome molecular inversion probe arrays were used to evaluate copy number imbalances (CNIs) in breast tumors from 960 early-stage patients with information a...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2796-3

    authors: Liu Y,Zhou R,Baumbusch LO,Tsavachidis S,Brewster AM,Do KA,Sahin A,Hortobagyi GN,Taube JH,Mani SA,Aarøe J,Wärnberg F,Børresen-Dale AL,Mills GB,Thompson PA,Bondy ML

    更新日期:2014-01-01 00:00:00

  • Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables.

    abstract:AIMS:Rapamycin and its analogues are currently being tested in clinical trials as novel-targeted anticancer agents. Pre-clinical studies that used breast cancer cell lines have suggested that p-Akt or p-S6K1 expressing tumors, as well as PTEN negative tumors, were sensitive to rapamycin. The aims of this study were to ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-007-9746-x

    authors: Noh WC,Kim YH,Kim MS,Koh JS,Kim HA,Moon NM,Paik NS

    更新日期:2008-08-01 00:00:00

  • Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review.

    abstract:BACKGROUND:Due to the high rate of febrile neutropenia (FN) with docetaxel-cyclophosphamide (DC) chemotherapy, primary FN prophylaxis is recommended. However, the optimal choice of prophylaxis [i.e., granulocyte-colony stimulating factors (G-CSF) or antibiotics] is unknown. A systematic review was performed to address ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-016-4028-0

    authors: Fernandes R,Mazzarello S,Stober C,Vandermeer L,Dudani S,Ibrahim MF,Majeed H,Perdrizet K,Shorr R,Hutton B,Fergusson D,Clemons M

    更新日期:2017-01-01 00:00:00

  • Phase I/II study of paclitaxel and vinorelbine in metastatic breast cancer.

    abstract::Paclitaxel and vinorelbine are among the most active new agents in metastatic breast cancer. Both in vitro and in vivo studies have shown that the combined administration of these two microtubule-targeting agents is feasible and worthwhile. Based on the promising preclinical data, patients with metastatic breast cance...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1023/a:1005848921895

    authors: Tortoriello A,Facchini G,Caponigro F,Santangelo M,Benassai G,Persico G,Citarella A,Carola M,Marzano N,Iaffaioli RV

    更新日期:1998-01-01 00:00:00

  • CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer.

    abstract::Overexpression of CD24 is an independent prognostic factor for breast cancer. Recently, two polymorphisms in the CD24 gene were linked to disease risk and progression in autoimmune diseases. Here, we evaluated the clinical relevance of these polymorphisms with respect to their potential to predict a pathologic complet...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10549-011-1759-9

    authors: Marmé F,Werft W,Walter A,Keller S,Wang X,Benner A,Burwinkel B,Sinn P,Hug S,Sohn C,Bretz N,Moldenhauer G,Rupp C,Rupp AK,Biakhov MY,Bottini A,Friedrichs K,Khailenko VA,Manikhas GM,Ruiz A,Sánchez-Rovira P,Santoro A

    更新日期:2012-04-01 00:00:00

  • Pre-morbid body-mass-index in breast cancer: reversed effect on survival in hormone receptor negative patients.

    abstract::The present study consists of 1,238 women with unilateral breast cancer treated with modified radical mastectomy living in the geographic area of Haukeland Hospital. Their weight and height had been measured years before presentation of the disease. Age-adjusted Quetelet's index (weight/height2) showed that obese wome...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01807157

    authors: Maehle BO,Tretli S

    更新日期:1996-01-01 00:00:00

  • The functional promoter polymorphism (-842G>C) in the PIN1 gene is associated with decreased risk of breast cancer in non-Hispanic white women 55 years and younger.

    abstract::PIN1, an isomerase that causes conformational changes in proteins, plays an important role in mammary epithelial cell growth both physiologically and pathologically. Thus, genetic variants in the PIN1 gene may alter protein function and cancer risk. We have previously demonstrated an association between a PIN1 promote...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-009-0682-9

    authors: Han CH,Lu J,Wei Q,Bondy ML,Brewster AM,Yu TK,Buchholz TA,Arun BK,Wang LE

    更新日期:2010-07-01 00:00:00

  • The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters.

    abstract::Breast cancer has been the most common malignant tumor among women in many large cities of China. The aim of this study was to clarify the prognostic significance of serum anti-p53 antibodies (p53 Abs) in Chinese patients of breast cancer. One hundred and forty-four patients with invasive ductal carcinoma of breast we...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-005-4321-9

    authors: Gao RJ,Bao HZ,Yang Q,Cong Q,Song JN,Wang L

    更新日期:2005-09-01 00:00:00

  • Is there a role for sentinel node biopsy in the pre-operative ultrasound positive axilla?

    abstract::Axillary management in breast cancer is becoming increasingly conservative. This approach is based on the identification of low axillary burden on sentinel node biopsy (SNB). The modern practice of routine pre-operative axillary ultrasound has meant that patients are 'fast tracked' to axillary node clearance (ANC) in ...

    journal_title:Breast cancer research and treatment

    pub_type: 社论

    doi:10.1007/s10549-017-4313-6

    authors: Ahmed M,Jozsa F,Douek M

    更新日期:2017-09-01 00:00:00

  • Assessing interactions between the associations of fibroblast growth factor receptor 2 common genetic variants and hormone receptor status with breast cancer risk.

    abstract::Fibroblast growth factor receptor 2 (FGFR2) is a member of a receptor tyrosine kinase gene superfamily, involved in cell growth, invasiveness, motility, and angiogenesis, which has attracted considerable attention as a candidate gene for breast cancer (BC) since it was first identified through genome-wide association ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析

    doi:10.1007/s10549-012-2343-7

    authors: Wang H,Yang Z,Zhang H

    更新日期:2013-01-01 00:00:00

  • Telomerase immortalization of human mammary epithelial cells derived from a BRCA2 mutation carrier.

    abstract::A novel human mammary epithelial cell line, HME348, was established from benign breast tissue from a 44-year-old germ-line BRCA2 mutation carrier with a history of stage 1 breast cancer. Mutation analysis showed that the patient had a known 6872del4 BRCA2 heterozygous mutation. The human mammary epithelial cells passa...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-006-9189-9

    authors: Lewis CM,Herbert BS,Bu D,Halloway S,Beck A,Shadeo A,Zhang C,Ashfaq R,Shay JW,Euhus DM

    更新日期:2006-09-01 00:00:00

  • Association study of susceptibility loci with specific breast cancer subtypes in Chinese women.

    abstract::To determine whether recent genome-wide association studies that reported 45 susceptibility loci in European women are also risk factors for breast cancer in Chinese women. We selected and genotyped 40 single nucleotide polymorphisms (SNPs) using the Sequenom iPlex platform in a female Chinese cohort of 2,901 breast c...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-014-3041-4

    authors: Zhang B,Li Y,Li L,Chen M,Zhang C,Zuo XB,Zhou FS,Liang B,Zhu J,Li P,Huang ZL,Xuan H,Li W,Chen ZD

    更新日期:2014-08-01 00:00:00

  • Digital image analysis of Ki67 proliferation index in breast cancer using virtual dual staining on whole tissue sections: clinical validation and inter-platform agreement.

    abstract:PURPOSE:The Ki67 proliferation index is a prognostic and predictive marker in breast cancer. Manual scoring is prone to inter- and intra-observer variability. The aims of this study were to clinically validate digital image analysis (DIA) of Ki67 using virtual dual staining (VDS) on whole tissue sections and to assess ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-4669-2

    authors: Koopman T,Buikema HJ,Hollema H,de Bock GH,van der Vegt B

    更新日期:2018-05-01 00:00:00

  • Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.

    abstract::The mutation pattern of breast cancer molecular subtypes is incompletely understood. The purpose of this study was to identify mutations in genes that may be targeted with currently available investigational drugs in the three major breast cancer subtypes (ER+/HER2-, HER2+, and Triple Negative). We extracted DNA from ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2035-3

    authors: Santarpia L,Qi Y,Stemke-Hale K,Wang B,Young EJ,Booser DJ,Holmes FA,O'Shaughnessy J,Hellerstedt B,Pippen J,Vidaurre T,Gomez H,Valero V,Hortobagyi GN,Symmans WF,Bottai G,Di Leo A,Gonzalez-Angulo AM,Pusztai L

    更新日期:2012-07-01 00:00:00

  • The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115).

    abstract:PURPOSE:In Brazil, the available cancer registries are deficient in number and quality and, hence, little information is known regarding sociodemographic, clinicopathological characteristics, treatment patterns, and outcomes of breast cancer (BC) patients. We performed the AMAZONA III/ GBECAM 0115 study and in this ana...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-05831-y

    authors: Rosa DD,Bines J,Werutsky G,Barrios CH,Cronemberger E,Queiroz GS,de Lima VCC,Freitas-Júnior R,Couto JD,Emerenciano K,Resende H,Crocamo S,Reinert T,Van Eyil B,Nerón Y,Dybal V,Lazaretti N,de Cassia Costamilan R,de Andrad

    更新日期:2020-10-01 00:00:00

  • Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients.

    abstract::Uncontrolled proliferation is one of the hallmarks of breast cancer. We have previously identified the human Ecd protein (human ortholog of Drosophila Ecdysoneless, hereafter called Ecd) as a novel promoter of mammalian cell cycle progression, a function related to its ability to remove the repressive effects of Rb-fa...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1946-8

    authors: Zhao X,Mirza S,Alshareeda A,Zhang Y,Gurumurthy CB,Bele A,Kim JH,Mohibi S,Goswami M,Lele SM,West W,Qiu F,Ellis IO,Rakha EA,Green AR,Band H,Band V

    更新日期:2012-07-01 00:00:00

  • Association of depression and anxiety disorder with the risk of mortality in breast cancer: A National Health Insurance Service study in Korea.

    abstract:PURPOSE:To examine whether depression, anxiety disorder, and their co-occurrence would increase the risk of mortality in patients with breast cancer, and whether antidepressant treatment would reduce the same. METHODS:Data were retrieved from the database of the Korean National Health Insurance Service. Of 145,251 pat...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05479-3

    authors: Shim EJ,Lee JW,Cho J,Jung HK,Kim NH,Lee JE,Min J,Noh WC,Park SH,Kim YS

    更新日期:2020-01-01 00:00:00

  • Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer.

    abstract::Docetaxel-containing chemotherapy improves disease-free survival (DFS) and overall survival in patients with early stage breast cancer. Bevacizumab improves response rate and DFS in metastatic breast cancer. However, adding antivascular endothelial growth factor therapy to anthracycline-containing chemotherapy may inc...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s10549-013-2764-y

    authors: Yardley DA,Hart L,Waterhouse D,Whorf R,Drosick DR,Murphy P,Badarinath S,Daniel BR,Childs BH,Burris H

    更新日期:2013-12-01 00:00:00

  • Genome-Wide Association Studies (GWAS) breast cancer susceptibility loci in Arabs: susceptibility and prognostic implications in Tunisians.

    abstract::Genome-wide Association Studies (GWAS) revealed novel genetic markers for breast cancer susceptibility. But little is known about the risk factors and molecular events associated with breast cancer in Arab Population. Therefore, we designed a broad study to investigate the susceptibility and prognostic implications of...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2202-6

    authors: Shan J,Mahfoudh W,Dsouza SP,Hassen E,Bouaouina N,Abdelhak S,Benhadjayed A,Memmi H,Mathew RA,Aigha II,Gabbouj S,Remadi Y,Chouchane L

    更新日期:2012-10-01 00:00:00

  • Analysis of HER2 and HER4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin).

    abstract:PURPOSE:When combined with anthracyclines, the humanized anti-HER2 monoclonal antibody trastuzumab (Herceptin) provides significant clinical benefit for women with HER2-overexpressing metastatic breast cancer. However, its use is limited by severe cardiotoxicity. To clarify whether myocardial HER2 and HER4 expression i...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/b:brea.0000003916.39959.73

    authors: Fuchs IB,Landt S,Bueler H,Kuehl U,Coupland S,Kleine-Tebbe A,Lichtenegger W,Schaller G

    更新日期:2003-11-01 00:00:00

  • Transforming growth factorβ1 L10P variant plays an active role on the breast cancer susceptibility in Caucasian: evidence from 10,392 cases and 11,697 controls.

    abstract::In view of the essential role of transforming growth factorβ1 (TGFB1) on both inhibiting the development of early benign breast tumors as well as promoting tumor invasion, the association of TGFB1 L10P polymorphism and breast cancer risk has been widely reported, but results of previous studies were somewhat contradic...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,meta分析,评审

    doi:10.1007/s10549-010-0843-x

    authors: Ma X,Chen C,Xiong H,Li Y

    更新日期:2010-11-01 00:00:00

  • Chemotherapy responsiveness of human breast tumors in the 6-day subrenal capsule assay: an update.

    abstract::Feasibility of utilizing the 6-day subrenal capsule (SRC) assay to screen drugs against fresh surgical explants of human tumors was confirmed by testing six clinically active chemotherapeutic agents against 141 human breast cancers. Response rates of the six drugs obtained in the assay compared favorably with clinical...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01806232

    authors: Bogden AE,Costanza ME,Reich SD,Griffin TW,Cobb WR

    更新日期:1983-01-01 00:00:00

  • Disseminated tumour cells in the bone marrow in early breast cancer: morphological categories of immunocytochemically positive cells have different impact on clinical outcome.

    abstract::Detection of disseminated tumour cells (DTCs) in bone marrow by immunocytochemistry (ICC) includes morphological evaluation of cytokeratin immunopositive cells. The aim of this study was to disclose the prognostic significance of different morphological categories of ICC-positive cells according to treatment status an...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2439-8

    authors: Synnestvedt M,Borgen E,Schlichting E,Schirmer CB,Renolen A,Giercksky KE,Nesland JM,Naume B

    更新日期:2013-04-01 00:00:00

  • Kinetic and morphometric responses of heterogeneous populations of NMU-induced rat mammary tumor cells to hormone and antipolyamine therapy in vivo.

    abstract::The present experiments were designed to evaluate in vivo the differential sensitivity of tumor cell subpopulations to hormone and polyamine manipulations using the hormone-responsive N-nitrosomethyl-urea (NMU)-induced rat mammary tumor. NMU tumor bearing rats were randomly assigned to control, ovariectomy, alpha-difl...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01806367

    authors: Manni A,Lancaster S,English H,Badger B,Lynch J,Demers L

    更新日期:1991-01-01 00:00:00

  • Histone acetylation decreased by estradiol in the MCF-7 human mammary cancer cell line.

    abstract::The effect of estradiol (E2) on the [3H]-acetylation of nuclear histones was studied in the MCF-7 human mammary cancer cell line in culture. Cells (approximately 10(8) were incubated with 8 x 10(-6) M [3H]-acetate in the absence (control) or in the presence of estradiol (10(-5)-10(-8) M). After 20 min incubation, the ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/BF01805980

    authors: Pasqualini JR,Mercat P,Giambiagi N

    更新日期:1989-10-01 00:00:00

  • Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer.

    abstract::Metastasis to the regional lymph nodes through the lymphatic vessels is a common step in the progression of cancer and an important prognostic factor in many types of cancer. Recent evidence suggests that VEGF-C promotes lymphangiogenesis, and that tumor lymphangiogenesis in turn promotes lymphatic metastasis. We have...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-004-5783-x

    authors: Nakamura Y,Yasuoka H,Tsujimoto M,Imabun S,Nakahara M,Nakao K,Nakamura M,Mori I,Kakudo K

    更新日期:2005-05-01 00:00:00

  • EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry.

    abstract::EMSY is a putative oncogene amplified in a minority of breast carcinomas, its protein product interacts with and transcriptionally silences BRCA2. We hypothesized that breast tumors from BRCA2 mutation carriers would be less likely than other familial breast cancers to exhibit EMSY amplification. As EMSY is located on...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1380-y

    authors: Bane AL,Mulligan AM,Pinnaduwage D,O'Malley FP,Andrulis IL

    更新日期:2011-06-01 00:00:00

  • Femara and the future: tailoring treatment and combination therapies with Femara.

    abstract::Long-term estrogen deprivation treatment for breast cancer can, in some patients, lead to the activation of alternate cellular pathways, resulting in the re-emergence of the disease. This is a distressing scenario for oncologists and patients, but recent intensive molecular and biochemical studies are beginning to unr...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-007-9697-2

    authors: Ellis M,Ma C

    更新日期:2007-01-01 00:00:00